Using Decision-Analytic Modeling to Isolate Interventions That Are Feasible, Efficient and Optimal: An Application from the Norwegian Cervical Cancer Screening Program

• Published in: Value in health Vol. 18; no. 8; pp. 1088 - 1097
• Main Authors: Pedersen, Kine, MPhil, Sørbye, Sveinung Wergeland, MD, PhD, Burger, Emily Annika, PhD, Lönnberg, Stefan, MD, PhD, Kristiansen, Ivar Sønbø, MD, PhD, MPH
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2015; Blackwell Publishers
• Subjects: Adult; Age Factors; Aged; Algorithms; Cervical Intraepithelial Neoplasia - diagnosis; Cervical Intraepithelial Neoplasia - economics; Colposcopy - economics; Cost-Benefit Analysis; decision analysis; decision making; Decision Trees; Early Detection of Cancer - economics; economic evaluation; Female; Humans; Internal Medicine; Middle Aged; Models, Econometric; Monte Carlo Method; Norway; Quality-Adjusted Life Years; Uterine Cervical Neoplasms - diagnosis; Uterine Cervical Neoplasms - economics; Norway; decision analysis; decision making; economic evaluation
• ISSN: 1098-3015; 1524-4733
• DOI: 10.1016/j.jval.2015.08.003

Abstract Background Decision makers often need to simultaneously consider multiple criteria or outcomes when deciding whether to adopt new health interventions. Objectives Using decision analysis within the context of cervical cancer screening in Norway, we aimed to aid decision makers in identifying a subset of relevant strategies that are simultaneously efficient, feasible, and optimal. Methods We developed an age-stratified probabilistic decision tree model following a cohort of women attending primary screening through one screening round. We enumerated detected precancers (i.e., cervical intraepithelial neoplasia of grade 2 or more severe (CIN2+)), colposcopies performed, and monetary costs associated with 10 alternative triage algorithms for women with abnormal cytology results. As efficiency metrics, we calculated incremental cost-effectiveness, and harm-benefit, ratios, defined as the additional costs, or the additional number of colposcopies, per additional CIN2+ detected. We estimated capacity requirements and uncertainty surrounding which strategy is optimal according to the decision rule, involving willingness to pay (monetary or resources consumed per added benefit). Results For ages 25 to 33 years, we eliminated four strategies that did not fall on either efficiency frontier, while one strategy was efficient with respect to both efficiency metrics. Compared with current practice in Norway, two strategies detected more precancers at lower monetary costs, but some required more colposcopies. Similar results were found for women aged 34 to 69 years. Conclusions Improving the effectiveness and efficiency of cervical cancer screening may necessitate additional resources. Although efficient and feasible, both society and individuals must specify their willingness to accept the additional resources and perceived harms required to increase effectiveness before a strategy can be considered optimal.